Press release

SeqOne Genomics appoints Martin Dubuc as Chief Executive Officer

SeqOne Genomics, an award-winning French HealthTech startup specializing in AI-powered clinical genomics, is pleased to announce the appointment of Martin Dubuc as its new Chief Executive Officer. Historic investors include Elaia, IRDI Capital Investissement, Merieux Equity Partners, Omnes, and Software Club.

Mr. Martin Dubuc joined SeqOne’s board of directors in October. He is a seasoned healthcare executive with global experience who most recently headed up Biogen’s Global Digital Health division, driving personalized and digital medicine. He brings over two decades of experience in the pharmaceutical industry at Pfizer, Merck&Co, Biogen, and thought leadership in digital health.

As part of the transition, Nicolas Philippe, PhD, co-founder and until then Chief Executive Officer, will become President and Chief Product & Scientific Officer, heading up research and product development of the proprietary SeqOne clinical genomics platform.

These appointments reflect SeqOne’s market leadership ambition and growth strategy across international markets and the biopharmaceutical industry.

Sacha Loiseau, Ph.D., chairperson of SeqOne Genomics’ Board, stated: “Under Nicolas’ visionary leadership, SeqOne has passed a multitude of important milestones across product development, clinical advancements, regulatory approvals, and commercial successes, notably in the blazingly fast development and launch of a best-in-class HRD test. We are thrilled to have Martin spearhead the next phase of SeqOne’s growth story as we scale up to become a global leader in the rapidly growing next-generation sequencing clinical informatics market. Martin’s strategic acumen as our chief executive, coupled with Nicolas’ deepened focus on our product innovation and science, positions SeqOne at the cusp of transformative success.” “SeqOne’s leading clinical genomics platform empowers genetics labs and healthcare professionals to improve patient care across multiple therapeutic areas. I am excited to join a highly talented and multidisciplinary team at this exciting time and with such an important mission of making personalized medicine a reality at scale, accessible to all”, commented Mr. Dubuc.

About SeqOne Genomics:

Founded in 2017, SeqOne Genomics, headquartered in Montpellier, France, is a fast-growing deep-tech company focused on turning genomic data into medically actionable insights in oncology and rare and inherited diseases. SeqOne clinical genomic analysis platform, powered by explainable AI, provides genomic labs and healthcare professionals with best-in-class accuracy, usability, and automation seamlessly across lab technologies.
By streamlining complex multi-omics analysis workflows, we pave the way for a new era of personalized healthcare at scale, where genetic testing becomes as routine as traditional blood work, radically enhancing health outcomes for all.

The company has won numerous awards, including the iLab award and the ARC Cancer Foundation’s Hélène Stark prize. It has been nominated twice for the prestigious Prix Galien award. Investors include Elaia, IRDI Capital Investissement, Merieux Equity Partners, Omnes, and Software Club.

Web: https://seqone.com
Contact: media@seqone.com



Published on 30 January 2024

Need help improving your genomic analysis process ?
We'd love to help !